Category Archives: Biotech Letter

Why This Biotech Owns The Aging Population Trade

Walking through the oncology ward at Cedars-Sinai last week, I noticed something interesting. The pharmacy techs were wheeling around more Amgen (AMGN) products than I’d seen in months. Repatha for cholesterol management, EVENITY for osteoporosis, and their expanding biosimilars portfolio. It got me thinking about why Wall Street keeps sleeping on this biotech behemoth. It’s […]

The Anti-Biotech Biotech

I was grabbing coffee with my old Marine buddy Mike last week when he asked me about biotech stocks. “John,” he said, “every time I buy one of these pharmaceutical companies, it’s like stepping on an IED. What am I missing?” I laughed because Mike’s not wrong. The biotech sector has been a graveyard for […]

The Orchard Strategy

Last month, I was in my doctor’s waiting room, watching the receptionist wrestle with three different computer systems just to book my checkup. She clicked through windows that looked like they belonged on a floppy disk. “This is why healthcare costs so much,” I thought. What I didn’t realize then was that I was watching […]

The Magic Word Isn’t Please

Three months ago, my neighbor ended up in the emergency room with chest pains. False alarm, thankfully, but what struck me was how quickly they ran a dozen different tests and had results back within hours. The attending physician mentioned their lab equipment had been recently upgraded to “some Danaher (DHR) system that’s basically magic.” […]

My Drill Sergeant’s Guide To Dividend Discipline

I’m looking at Johnson & Johnson’s (JNJ) latest quarterly numbers from my Lake Tahoe office, and I keep thinking about something my drill sergeant used to say in boot camp: “The best soldiers are the ones nobody notices until the shooting starts.” JNJ is that soldier right now. While everyone’s losing their minds over the […]